Bio-Path price target raised to $40 from $12 at Roth MKM

Roth MKM raised the firm’s price target on Bio-Path to $40 from $12 and keeps a Buy rating on the shares after its Q4 results earlier this month while also reflecting its recent 1-for-20 reverse split, model revisions, and capital raise. The company’s combination therapy with prexigebersen in AML showed remarkable efficacy and safety, and both the Phase 1/1b BP1002 trials in rel/ref Chronic Lymphocytic Leukemia and rel/ref Acute Myeloid Leukemia completed their first dose cohorts and should more swiftly enroll subsequent cohorts, the analyst tells investors in a research note.